Literature DB >> 7946947

Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase.

I Stancovski1, M Sela, Y Yarden.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7946947     DOI: 10.1007/978-1-4615-2592-9_9

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


× No keyword cloud information.
  5 in total

Review 1.  ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.

Authors:  R Pinkas-Kramarski; I Alroy; Y Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  Bivalence of EGF-like ligands drives the ErbB signaling network.

Authors:  E Tzahar; R Pinkas-Kramarski; J D Moyer; L N Klapper; I Alroy; G Levkowitz; M Shelly; S Henis; M Eisenstein; B J Ratzkin; M Sela; G C Andrews; Y Yarden
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

3.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.

Authors:  E Tzahar; H Waterman; X Chen; G Levkowitz; D Karunagaran; S Lavi; B J Ratzkin; Y Yarden
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

4.  Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.

Authors:  A E Lenferink; R Pinkas-Kramarski; M L van de Poll; M J van Vugt; L N Klapper; E Tzahar; H Waterman; M Sela; E J van Zoelen; Y Yarden
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

Review 5.  EGFR Signaling in Lung Fibrosis.

Authors:  Fabian Schramm; Liliana Schaefer; Malgorzata Wygrecka
Journal:  Cells       Date:  2022-03-14       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.